Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Marianne Bonner, CPCU, ARM, covers business insurance topics for Investopedia, building on 30 years of experience working in the insurance industry. She has written extensively for The Risk Report, ...